ATYR — aTYR PHARMA INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1339970 ·
Last close
$0.31
Market Cap
$29.92M
52W High
$1.12
52W Low
$0.28
ADV30
5,373,740
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,881,000 | -10,309,000 | 69,825,000 | 16,160,000 | 21,231,000 |
| Mar 2026 | 0 | — | -11,436,000 | -10,791,000 | 79,654,000 | 10,008,000 | 21,913,000 |
| Dec 2025 | 0 | — | -14,796,000 | -13,963,000 | 93,003,000 | 10,743,000 | 25,715,000 |
| Sep 2025 | 190,000 | — | -26,745,000 | -25,744,000 | 106,652,000 | 6,150,000 | 26,608,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,083,000
Investing CF
$10,861,000
Financing CF
$47,241,000
CapEx
$-231,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-616,955,000
Inventory
—
Receivables
$477,000
ST Investments
$56,505,000
EBIT TTM
$-73,290,000
Pretax Income TTM
$-70,034,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$190,000
EBITDA
$-63,197,000
Free Cash Flow
$-31,708,250
Enterprise Value
$-4,155,024
Total Cash
$57,418,000
Total Debt
$11,299,000
Shares Out
98,087,425
Trailing EPS
$-0.63
Book Value
$0.50
ROE
-98.7%
ROA
-46.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 190,000 | -77,627,000 | -74,118,000 | 93,003,000 | 25,715,000 | 67,480,000 | -61,986,000 |
| Dec 2024 | 235,000 | -67,914,000 | -64,023,000 | 96,830,000 | 26,998,000 | 70,019,000 | -69,119,000 |
| Dec 2023 | 353,000 | -54,919,000 | -50,389,000 | 120,653,000 | 30,183,000 | 90,658,000 | -33,221,000 |
| Dec 2022 | 10,386,000 | -46,404,000 | -45,338,000 | 95,786,000 | 24,502,000 | 71,464,000 | -41,886,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-31,186,000
OpCashFlow TTM
$0
Assets (Latest)
$93,003,000
Forward EPS
$-0.47
Max Pain — expiry 2028-01-21
max pain strike: $0.50 · spot: $0.30 · call oi: 2,711 · put oi: 4
Expected Move to 2028-01-21:
±$0.40
(134.36%) —
implied range
$-0.10 –
$0.70
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALGS | Aligos Therapeutics, Inc. | $30.00M | $5.51 | — |
| EVAX | Evaxion A/S | $30.13M | $3.34 | — |
| CVM | CEL SCI CORP | $29.37M | $1.67 | — |
| LONA | LeonaBio, Inc. | $30.62M | $3.25 | — |
| QNCX | Quince Therapeutics, Inc. | $31.53M | $31.00 | — |
News headlines (Yahoo Finance, 1h cache)
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
2026-09-24 14:59 · Yahoo
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
2026-09-24 10:00 · Yahoo
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
2026-09-08 14:31 · Yahoo
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
2026-09-01 20:36 · Yahoo
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans
2026-08-07 20:39 · Yahoo
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
2026-08-07 20:01 · Yahoo
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
2026-07-15 12:00 · Yahoo
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
2026-05-15 12:00 · Yahoo
aTyr Pharma to Participate in Upcoming Investor Conferences
2026-05-13 20:01 · Yahoo
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
2026-05-12 00:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.